Seven-day antibiotic therapy for Enterobacterales bacteremia in high-risk neutropenic patients: toward a new paradigm.

Fabián HerreraDiego TorresAna LabordeRosana JordánLucas TulaNoelia MañezMaría Laura PereyraNadia SuchowierchaLorena BerruezoCarlota GudiolMaría Luz González IbáñezMaría José EusebioSandra LambertLaura BarcánInés Roccia RossiFederico NicolaMagdalena PenniniRenata MongeMiriam BlancoMariángeles VisúsMariana ReynaldiRuth CarboneFernando PasteránAlejandra CorsoMelina RapoportAlberto Angel Carenanull null

Published in: European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology (2024)

These data suggest that seven-day antibiotic therapy might be adequate for patients with high-risk neutropenia and Enterobacterales bacteremia, who receive appropriate empirical therapy, with clinical response and infection source control.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
peritoneal dialysis
stem cells
big data
patient reported outcomes